Similarly, the 5-year cancer-specific overall survival (OS) rates of PD-L1-negative, PD-L1-positive, CD155-negative, and CD155-positive patients were 96.3%, 75.3%, 95.5%, and 89.1%, respectively. This evidence concerns the gene PVR and cancer.